DOCSLIB.ORG

Use of Pembrolizumab with Or Without Pomalidomide in HIV-Associated Non-Hodgkin's Lymphoma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Use of Pembrolizumab with Or Without Pomalidomide in HIV-Associated Non-Hodgkin's Lymphoma Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-002097 on 19 February 2021. Downloaded from Use of pembrolizumab with or without pomalidomide in HIV- associated non- Hodgkin’s lymphoma 1 1 1 1 Kathryn Lurain , Ramya Ramaswami, Ralph Mangusan, Anaida Widell, Irene Ekwede,1 Jomy George,2 Richard Ambinder,3 Martin Cheever,4 5 1 6 James L Gulley , Priscila H Goncalves, Hao- Wei Wang, 1,7 1 Thomas S Uldrick , Robert Yarchoan To cite: Lurain K, ABSTRACT INTRODUCTION Ramaswami R, Mangusan R, Background Non- Hodgkin’s lymphoma (NHL) is With current combination antiretroviral et al. Use of pembrolizumab currently the most common malignancy among people therapy (ART), the most common cancer with or without pomalidomide in living with HIV (PLWH) in the USA. NHL in PLWH is more HIV- associated among people living with HIV (PLWH) in the frequently associated with oncogenic viruses than NHL in 1 non- Hodgkin’s lymphoma. USA is non-Hodgkin's lymphoma (NHL). immunocompetent individuals and is generally associated Journal for ImmunoTherapy There is an 11- fold to 17- fold increased life- of Cancer 2021;9:e002097. with increased PD-1 expression and T cell exhaustion. An effective immune-based second-line approach that is less time risk of NHL in PLWH compared with doi:10.1136/jitc-2020-002097 + immunosuppressive than chemotherapy may decrease the general population, due in part to CD4 T cell lymphopenia but also to immune ► Additional material is infection risk, improve immune control of oncogenic published online only. To view, viruses, and ultimately allow for better lymphoma control. dysregulation, B cell activation, and immune please visit the journal online Methods We conducted a retrospective study of exhaustion from chronic viral antigen stimu- (http:// dx. doi. org/ 10. 1136/ jitc- patients with HIV- associated lymphomas treated with lation.2 3 Similar to the general population, 2020- 002097). pembrolizumab±pomalidomide in the HIV and AIDS diffuse large B cell lymphoma (DLBCL) is Malignancy Branch, Center for Cancer Research, National the most common subtype, but there are also Accepted 13 January 2021 Cancer Institute. rare subtypes that occur almost exclusively in Results We identified 10 patients with stage IV relapsed and/or primary refractory HIV-associa ted NHL PLWH, such as primary effusion lymphoma who were treated with pembrolizumab, an immune (PEL) and plasmablastic lymphoma (PBL). In checkpoint inihibitor, with or without pomalidomide. Five PLWH, DLBCL and PBL are frequently asso- patients had primary effusion lymphoma (PEL): one had ciated with Epstein- Barr virus (EBV). Kaposi http://jitc.bmj.com/ germinal center B cell- like (GCB) diffuse large B cell sarcoma herpesvirus (KSHV, also known as lymphoma (DLBCL); two had non-GCB DLBCL; one had human herpesvirus 8) is the etiologic agent aggressive B cell lymphoma, not otherwise specified; of PEL, with EBV coinfection also present and one had plasmablastic lymphoma. Six patients in the vast majority of cases.4 Several factors received pembrolizumab alone at 200 mg intravenously are believed to contribute to the increased every 3 weeks, three received pembrolizumab 200 mg intravenously every 4 weeks plus pomalidomide 4 mg risk of virus- associated NHL in PLWH. HIV- on September 28, 2021 by guest. Protected copyright. orally every day for days 1–21 of a 28- day cycle; and associated immunosuppression causes a loss one sequentially received pembrolizumab alone and of virus- specific T cells allowing decreased then pomalidomide alone. The response rate was 50% control of EBV- infected or KSHV- infected B with particular benefit in gammaherpesvirus-associa ted cell, increasing B cell activation and the risk tumors. The progression-free survival was 4.1 months of malignant B cell transformation.5 Both (95% CI: 1.3 to 12.4) and overall survival was 14.7 months EBV and KSHV are able to evade immune (95% CI: 2.96 to not reached). Three patients with PEL had detection and maintain infection in host leptomeningeal disease: one had a complete response © Author(s) (or their B cells through downregulation of expres- and the other two had long-term disease control. There employer(s)) 2021. Re- use sion of immune surface markers, which are permitted under CC BY-NC. No were four immune-rela ted adverse events (irAEs), all commercial re- use. See rights CTCAEv5 grade 2–3; three of the four patients were able essential for T cell and natural killer (NK) and permissions. Published by to continue receiving pembrolizumab. No irAEs occurred in cell immune surveillance, and this process BMJ. patients receiving the combination of pembrolizumab and may work in tandem with HIV- induced For numbered affiliations see pomalidomide. immunosuppression.6 end of article. Conclusions Treatment of HIV-associa ted NHL with PD-1 inhibitors, such as pembrolizumab pembrolizumab with or without pomalidomide elicited Correspondence to and nivolumab, have proven effective in responses in several subtypes of HIV-associa ted NHL. This Dr Kathryn Lurain; many cancer subtypes, particularly those with approach is worth further study in PLWH and NHL. 7 kathryn. lurain@ nih. gov neoantigens from a high mutational burden. Lurain K, et al. J Immunother Cancer 2021;9:e002097. doi:10.1136/jitc-2020-002097 1 Open access J Immunother Cancer: first published as 10.1136/jitc-2020-002097 on 19 February 2021. Downloaded from Checkpoint inhibitors are potentially attractive agents addition of pomalidomide, and in this manuscript, we in PLWH as they do not cause further immunosuppres- review our experience with this salvage therapy for HIV- sion, unlike traditional cytotoxic chemotherapies and associated NHL. radiotherapy, and also because of the increase in PD-1- expressing exhausted T cells seen in PLWH compared with the general population.8 While these agents have had relatively disappointing results so far as single agents PATIENTS AND METHODS in aggressive NHL in the immunocompetent population, Study design and patient selection EBV- encoded and/or KSHV- encoded foreign antigens We conducted a retrospective study of all identified patients in HIV- associated NHL may render these tumors poten- with HIV- associated lymphomas treated with pembroli- tially more susceptible to such therapy.9 10 Recent clinical zumab±pomalidomide in the HIV and AIDS Malignancy trials have provided evidence that these agents are safe in Branch, Center for Cancer Research, National Cancer PLWH and have anti- tumor activity in a subset of cases.11 12 Institute (NCI). All patients were participating in one Pomalidomide is a third generation analog of thalid- or more clinical studies (NCT00006518, NCT00092222, omide with immunomodulatory, antiangiogenic, and NCT01419561) and one clinical trial (NCT02595866). antineoplastic properties. Thalidomide and its analogs all All cases were pathologically confirmed in the Labora- work by binding to and modulating the activity of cere- tory of Pathology, NCI, and evaluated at the time of active blon. Pomalidomide is approved by the United States disease. Diagnoses were based on cytopathology and/or Food and Drug Administration (FDA) for the treatment H&E staining of tissue supported by immunohistochem- of multiple myeloma and Kaposi sarcoma, and has been istry. Leptomeningeal involvement of NHL was deter- proven to be safe in PLWH.13 Pomalidomide also has mined by cytopathology and/or flow cytometry of the known activity in certain types of NHL.14 There may be cerebrospinal fluid (CSF), and patients with CSF involve- direct anti- lymphoma activity in part via downregula- ment were followed serially with cytopathology and flow tion of IRF4/MUM1 expression, which is common in cytometry. KSHV tumor status was confirmed by staining HIV- associated NHL.15 16 Pomalidomide can enhance T for latency- associated nuclear antigen (anti-ORF73 rat and NK cell activation, and there is also evidence that it mAB, Advanced Biotechnologies, Eldersburg, Maryland, may render EBV- infected or KSHV- infected tumor cells USA). EBV tumor status was evaluated by in situ hybrid- visible to the immune system by reversing EBV-induced ization against EBV- encoded small RNA. Clinical records and KSHV- induced downregulation of immune surface were reviewed for baseline clinical laboratory parameters markers, such as MHC-1, ICAM-1, and CD86.17 18 Another prior to initiation of therapy. NHL staging and response clinically relevant aspect of pomalidomide is its ability to to treatment were determined according to the Lugano penetrate the central nervous system (CNS), as leptome- classification for NHL, and restaging was performed ningeal involvement is more frequent in HIV- associated every three cycles or more frequently if progressive 23 NHL.14 19 disease was suspected. Disease stabilization of leptome- The standard treatment for NHL after progression on ningeal disease was defined by the lack of new neurologic http://jitc.bmj.com/ or after front- line chemotherapy is second- line combina- symptoms or MRI findings that could be attributed to + + tion chemotherapy, often containing a platinum agent, disease. HIV viral loads and CD4 and CD8 T cell counts followed by autologous hematopoietic stem cell trans- were generally measured every 3 months unless there was plant.20 21 This approach does not generally differ for clinical indication to measure more frequently. Immune- HIV- associated NHL; however, a second-line approach related adverse events (irAEs) were graded according to that spares not only T cells,
Load more

Recommended publications
  • A Patient with Plasmablastic Lymphoma Achieving Long-Term
    Broccoli et al. BMC Cancer (2018) 18:645 https://doi.org/10.1186/s12885-018-4561-9 CASE REPORT Open Access A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report Alessandro Broccoli*, Laura Nanni, Vittorio Stefoni, Claudio Agostinelli, Lisa Argnani, Michele Cavo and Pier Luigi Zinzani Abstract Background: No standard of care is established for plasmablastic lymphoma (PBL) and prognosis remains extremely poor, given that patients relapse early after chemotherapy and display resistance to commonly applied cytostatic drugs. Case presentation: We report a case of nodal, HIV-unrelated PBL in a patient who achieved and maintained a very long lasting complete remission after an intensive therapy consisting consisting of thalidomide plus dexamethasone followed by a consolidation with double autologous stem cell transplantation. Our approach was based on the full application of a standard multiple myeloma treatment and, to the best of our knowledge, it represents the only reported experience so far. This treatment was overall well tolerated. Conclusions: Multiple myeloma-like treatment may represent a possible alternative to intensive lymphoma-directed therapies. Background Case presentation Plasmablastic lymphoma (PBL) is a rare and highly A 46-year old Italian female presented in June 2007 aggressive subtype of diffuse large B-cell lymphoma, with 3 enlarged lymph nodes in her left groin without characterized by diffuse
    [Show full text]
  • COMPARISON of the WHO ATC CLASSIFICATION & Ephmra/Intellus Worldwide ANATOMICAL CLASSIFICATION
    COMPARISON OF THE WHO ATC CLASSIFICATION & EphMRA/Intellus Worldwide ANATOMICAL CLASSIFICATION: VERSION June 2019 2 Comparison of the WHO ATC Classification and EphMRA / Intellus Worldwide Anatomical Classification The following booklet is designed to improve the understanding of the two classification systems. The development of the two systems had previously taken place separately. EphMRA and WHO are now working together to ensure that there is a convergence of the 2 systems rather than a divergence. In order to better understand the two classification systems, we should pay attention to the way in which substances/products are classified. WHO mainly classifies substances according to the therapeutic or pharmaceutical aspects and in one class only (particular formulations or strengths can be given separate codes, e.g. clonidine in C02A as antihypertensive agent, N02C as anti-migraine product and S01E as ophthalmic product). EphMRA classifies products, mainly according to their indications and use. Therefore, it is possible to find the same compound in several classes, depending on the product, e.g., NAPROXEN tablets can be classified in M1A (antirheumatic), N2B (analgesic) and G2C if indicated for gynaecological conditions only. The purposes of classification are also different: The main purpose of the WHO classification is for international drug utilisation research and for adverse drug reaction monitoring. This classification is recommended by the WHO for use in international drug utilisation research. The EphMRA/Intellus Worldwide classification has a primary objective to satisfy the marketing needs of the pharmaceutical companies. Therefore, a direct comparison is sometimes difficult due to the different nature and purpose of the two systems.
    [Show full text]
  • Australian Pi – Pomalyst (Pomalidomide) Capsules
    AUSTRALIAN PI – POMALYST (POMALIDOMIDE) CAPSULES Teratogenic effects: Pomalyst (pomalidomide) is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If pomalidomide is taken during pregnancy, it may cause birth defects or death to an unborn baby. Women should be advised to avoid pregnancy whilst taking Pomalyst (pomalidomide), during dose interruptions, and for 4 weeks after stopping the medicine. 1 NAME OF THE MEDICINE Australian Approved Name: pomalidomide 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 mg capsule contains 1 mg pomalidomide. Each 2 mg capsule contains 2 mg pomalidomide. Each 3 mg capsule contains 3 mg pomalidomide. Each 4 mg capsule contains 4 mg pomalidomide. For the full list of excipients, see Section 6.1. Description Pomalidomide is a yellow solid powder. It is practically insoluble in water over the pH range 1.2-6.8 and is slightly soluble (eg. acetone, methylene chloride) to practically insoluble (eg. heptanes, ethanol) in organic solvents. Pomalidomide has a chiral carbon atom and exists as a racemic mixture of the R(+) and S(-) enantiomers. 3 PHARMACEUTICAL FORM Pomalyst (pomalidomide) 1 mg capsules: dark blue/yellow size 4 gelatin capsules marked “POML” in white ink and “1 mg” in black ink. Each 1 mg capsule contains 1 mg of pomalidomide. Pomalyst (pomalidomide) 2 mg capsules: dark blue/orange size 2 gelatin capsules marked “POML 2 mg” in white ink. Each 2 mg capsule contains 2 mg of pomalidomide. Pomalyst (pomalidomide) 3 mg capsules: dark blue/green size 2 gelatin capsules marked “POML 3 mg” in white ink.
    [Show full text]
  • Pomalidomide the POMALYST® Program
    Pomalidomide The POMALYST® Program Overview Multiple myeloma is a type of cancer that begins in plasma cells in bone marrow. Plasma cells are white blood cells that make antibodies. The abnormal plasma cells build up in the bone marrow and sometimes in the solid part of the bone. Pomalidomide (brand name Pomalyst®) is approved to treat certain patients with multiple myeloma, but only under a restricted distribution program. Before you start taking this drug, you and your loved ones should read the important information in this brochure about the medication, side effects, and the rules you must follow if you choose pomalidomide, including the requirement to use birth control. Safety Pomalidomide is similar to the drug thalidomide and can cause the same life threatening birth defects. Both medications are approved by the Food and Drug Administration (FDA) to treat multiple myeloma within restricted distribution programs. For pomalidomide, the program is called Pomalyst REMS™ (Risk Evaluation and Mitigation Strategy). The program is in place to make sure that everyone is following the established safety guidelines. Only providers (doctors, nurse practitioners, etc.) and pharmacies certified by this program can write prescriptions for this medication or dispense it. To be considered for pomalidomide: • you must have already tried at least 2 other therapies, including lenalidomide and bortezomib • your disease must have progressed within 60 days of completing your last therapy • you must enroll in the Pomalyst REMS program and agree to comply with the program’s requirements (detailed in this brochure) Your healthcare provider will counsel you about the risks and benefits of this therapy.
    [Show full text]
  • Australian Public Assessment Report for Apremilast
    Australian Public Assessment Report for Apremilast Proprietary Product Name: Otezla Sponsor: Celgene Pty Ltd October 2015 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) · The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. · The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. · The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. · The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. · To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs · An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. · AusPARs are prepared and published by the TGA. · An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. · An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. · A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • Extracavitary/Solid Variant of Primary Effusion Lymphoma Yoonjung Kim, Mda,1, Vasiliki Leventaki, Mda, Feriyl Bhaijee, Mbchbb, ⁎ Courtney C
    Available online at www.sciencedirect.com Annals of Diagnostic Pathology 16 (2012) 441–446 Extracavitary/solid variant of primary effusion lymphoma Yoonjung Kim, MDa,1, Vasiliki Leventaki, MDa, Feriyl Bhaijee, MBChBb, ⁎ Courtney C. Jackson, MDb, L. Jeffrey Medeiros, MDa, Francisco Vega, MD PhDa, aDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA bDepartment of Pathology, University of Mississippi Medical Center, Jackson, MS, USA Abstract Primary effusion lymphoma (PEL) is a distinct clinicopathologic entity associated with human herpesvirus 8 (HHV8) infection that mostly affects patients with immunodeficiency. Primary effusion lymphoma usually presents as a malignant effusion involving the pleural, peritoneal, and/or pericardial cavities without a tumor mass. Rare cases of HHV8-positive lymphoma with features similar to PEL can present as tumor masses in the absence of cavity effusions and are considered to represent an extracavitary or solid variant of PEL. Here, we report 3 cases of extracavitary PEL arising in human immunodeficiency virus–infected men. Two patients had lymphadenopathy and underwent lymph node biopsy. One patient had a mass involving the ileum and ascending colon. In lymph nodes, the tumor was predominantly sinusoidal. The tumor involving the ileum and ascending colon presented as 2 masses, 12.5 × 10.6 × 2.6 cm in the colon and 3.6 × 2.7 × 1.9 cm in the ileum. In each case, the neoplasms were composed of large anaplastic cells, and 2 cases had “hallmark cells.” Immunohistochemistry showed that all cases were positive for HHV8 and CD138. One case also expressed CD4 and CD30, and 1 case was positive for Epstein-Barr virus–encoded RNA.
    [Show full text]
  • Unsupported Price Increase Report
    Unsupported Price Increase Report 2019 Assessment October 8, 2019 (Updated November 6, 2019) ©Institute for Clinical and Economic Review, 2019 Authors David M. Rind, MD, MSc Eric Borrelli, PharmD, MBA Chief Medical Officer Evidence Synthesis Intern Institute for Clinical and Economic Review Institute for Clinical and Economic Review Foluso Agboola, MBBS, MPH Steven D. Pearson, MD, MSc Director, Evidence Synthesis President Institute for Clinical and Economic Review Institute for Clinical and Economic Review Varun M. Kumar, MBBS, MPH, MSc (Former) Associate Director of Health Economics Institute for Clinical and Economic Review None of the above authors disclosed any conflicts of interest. DATE OF PUBLICATION: October 8, 2019 (Updated November 6, 2019) We would also like to thank Laura Cianciolo and Maria M. Lowe for their contributions to this report. ©Institute for Clinical and Economic Review, 2019 Page ii Unsupported Price Increase Report About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation for a more effective, efficient, and just health care system. More information about ICER is available at http://www.icer-review.org. The funding for this report comes from the Laura and John Arnold Foundation. No funding for this work comes from health insurers, pharmacy benefit managers (PBMs), or life science companies. ICER receives approximately 21% of its overall revenue from these health industry organizations to run a separate Policy Summit program, with funding approximately equally split between insurers/PBMs and life science companies.
    [Show full text]
  • Primary Effusion Lymphoma Occurring in the Setting of Transplanted Patients
    Zanelli et al. BMC Cancer (2021) 21:468 https://doi.org/10.1186/s12885-021-08215-7 RESEARCH ARTICLE Open Access Primary effusion lymphoma occurring in the setting of transplanted patients: a systematic review of a rare, life-threatening post-transplantation occurrence Magda Zanelli1*† , Francesca Sanguedolce2†, Maurizio Zizzo3,4, Andrea Palicelli1, Maria Chiara Bassi5, Giacomo Santandrea1, Giovanni Martino6, Alessandra Soriano7, Cecilia Caprera8, Matteo Corsi8, Stefano Ricci1, Linda Ricci8 and Stefano Ascani8 Abstract Background: Primary effusion lymphoma is a rare, aggressive large B-cell lymphoma strictly linked to infection by Human Herpes virus 8/Kaposi sarcoma-associated herpes virus. In its classic form, it is characterized by body cavities neoplastic effusions without detectable tumor masses. It often occurs in immunocompromised patients, such as HIV- positive individuals. Primary effusion lymphoma may affect HIV-negative elderly patients from Human Herpes virus 8 endemic regions. So far, rare cases have been reported in transplanted patients. The purpose of our systematic review is to improve our understanding of this type of aggressive lymphoma in the setting of transplantation, focusing on epidemiology, clinical presentation, pathological features, differential diagnosis, treatment and outcome. The role of assessing the viral serological status in donors and recipients is also discussed. Methods: We performed a systematic review adhering to the PRISMA guidelines. The literature search was conducted on PubMed/MEDLINE, Web of Science, Scopus, EMBASE and Cochrane Library, using the search terms “primary effusion lymphoma” and “post-transplant”. Results: Our search identified 13 cases of post-transplant primary effusion lymphoma, predominantly in solid organ transplant recipients (6 kidney, 3 heart, 2 liver and 1 intestine), with only one case after allogenic bone marrow transplantation.
    [Show full text]
  • Plasmablastic Lymphomas and Plasmablastic Plasma Cell Myelomas Have Nearly Identical Immunophenotypic Profiles
    Modern Pathology (2005) 18, 806–815 & 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles Francisco Vega1, Chung-Che Chang2, Leonard J Medeiros3, Mark M Udden4, Jeong Hee Cho-Vega5, Ching-Ching Lau6, Chris J Finch1, Regis A Vilchez4,7, David McGregor1 and Jeffrey L Jorgensen3 1Department of Pathology, Baylor College of Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Hematopathology, The Methodist Hospital, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 3Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4Department of Medicine, Baylor College of Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 5Department of Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 6Department of Pediatrics, Baylor College of Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA and 7Department of Molecular Virology and Microbiology, Baylor College of Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA Plasmablastic lymphoma is an aggressive neoplasm that shares many cytomorphologic and immunopheno- typic features with plasmablastic plasma cell myeloma. However, plasmablastic lymphoma is listed in the World Health Organization (WHO) classification as a variant of diffuse large B-cell lymphoma. To characterize the relationship between plasmablastic lymphoma and plasmablastic plasma cell myeloma, we performed immunohistochemistry using a large panel of B-cell and plasma cell markers on nine cases of plasmablastic lymphoma and seven cases of plasmablastic plasma cell myeloma with and without HIV/AIDS.
    [Show full text]
  • Samaritan Fund
    Items supported by the Samaritan Fund (a) Non-drug Items supported by the Fund (b) Other items supported by the Samaritan Fund Mechanism (c) Self-financed Drugs supported by the Samaritan Fund (SF) and Community Care Fund (CCF) Medical Assistance Programme (First Phase Programme) (for specified self- financed cancer drugs) (a) Non-drug Items supported by the Fund 1. Percutaneous Transluminal Coronary Angioplasty (PTCA) and other consumables for interventional cardiology 2. Cardiac Pacemakers 3. Myoelectric Prosthesis 4. Custom-made Prosthesis 5. Appliances for prosthetic and orthotic services, physiotherapy and occupational therapy services (e.g. prosthesis) 6. Home use equipment and appliances (e.g. wheelchair, replacement of external speech processor for patients done with cochlear implant) 7. Gamma knife surgery 8. Harvesting of marrow in a foreign country for marrow transplant The Fund will only support the model which can meet the basic medical needs of the patients. (b) Other items supported by the Samaritan Fund Mechanism 1. Positron Emission Tomography (PET) service (c) Drugs supported by the Samaritan Fund The following specific self-financed drugs are supported by the Samaritan Fund: Item Drug Types of Clinical indications diseases 1 Abatacept Rheumatology Rheumatoid arthritis 2a Adalimumab Dermatology Severe psoriasis 2b Ophthalmology Non-infectious intermediate, posterior and panuveitis 2c Paediatric chronic non-infectious anterior uveitis 2d Rheumatology Ankylosing spondylitis 2e Juvenile idiopathic arthritis 2f Psoriatic
    [Show full text]
  • Plasmablastic Lymphoma Masquerading Solitary Plasmacytoma in an Immunocompetent Patient Rodrigo Diaz,1,2 Julan Amalaseelan,2 Louise Imlay-Gillespie3
    Rare disease BMJ Case Reports: first published as 10.1136/bcr-2018-225374 on 21 October 2018. Downloaded from CASE REPORT Plasmablastic lymphoma masquerading solitary plasmacytoma in an immunocompetent patient Rodrigo Diaz,1,2 Julan Amalaseelan,2 Louise Imlay-Gillespie3 1Radiation Oncology, Northern SUMMARY symptoms. The initial CT of lumbar spine showed NSW Local Health District, We report a case of a middle-aged woman who initially a pathological fracture in L5. Subsequent MRI of Lismore, New South Wales, presented with a painful solitary destructive lesion at lumbosacral spine demonstrated posterior extra- Australia fifth lumbar vertebra.T he initial diagnosis of plasma dural mass at L5 level with compression of L5 2Radiation Oncology, Northern cell neoplasm was made based on limited histological nerve root (figure 1). She proceeded to have NSW Cancer Institute, Lismore, laminectomy and surgical decompression. Intra- New South Wales, Australia information obtained from fragmented tissue sample. 3Lismore Cancer Care and Clinicopathological findings were consistent with operatively fibrous organising lesion intimately Haematology Unit, Northern a solitary plasmacytoma, and she was treated with associated with theca at S1 level was identified. NSW Local Health District, definitive radiotherapy.A month after completing The culture from surgical material grew Staphy- Lismore, New South Wales, radiotherapy, she was found to have multiple liver lococcus epidermidis, probably from contamina- Australia lesions. Subsequent liver biopsy confirmed plasmablastic tion. Nevertheless, she was treated with antibiotic lymphoma (PBL). She was treated with multiple lines therapy for extended period. Correspondence to of chemo/immunotherapy regimens with limited or no The histopathological examination of surgical Dr Rodrigo Diaz, response.
    [Show full text]
  • Plasmablastic Lymphoma Phenotype Is Determined by Genetic Alterations
    Modern Pathology (2017) 30, 85–94 © 2017 USCAP, Inc All rights reserved 0893-3952/17 $32.00 85 Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1 Santiago Montes-Moreno1,2, Nerea Martinez-Magunacelaya2, Tomás Zecchini-Barrese1, Sonia Gonzalez de Villambrosía3, Emma Linares1, Tamara Ranchal4, María Rodriguez-Pinilla4, Ana Batlle3, Laura Cereceda-Company2, Jose Bernardo Revert-Arce5, Carmen Almaraz2 and Miguel A Piris1,2 1Pathology Department, Servicio de Anatomía Patológica, Hospital Universitario Marqués de Valdecilla/ IDIVAL, Santander, Spain; 2Laboratorio de Genómica del Cáncer, IDIVAL, Santander, Spain; 3Hematology Department, Cytogenetics Unit, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain; 4Pathology Department, Fundación Jiménez Díaz, Madrid, Spain and 5Valdecilla Tumor Biobank Unit, HUMV/IDIVAL, Santander, Spain Plasmablastic lymphoma is an uncommon aggressive non-Hodgkin B-cell lymphoma type defined as a high- grade large B-cell neoplasm with plasma cell phenotype. Genetic alterations in MYC have been found in a proportion (~60%) of plasmablastic lymphoma cases and lead to MYC-protein overexpression. Here, we performed a genetic and expression profile of 36 plasmablastic lymphoma cases and demonstrate that MYC overexpression is not restricted to MYC-translocated (46%) or MYC-amplified cases (11%). Furthermore, we demonstrate that recurrent somatic mutations in PRDM1 are found in 50% of plasmablastic lymphoma cases (8 of 16 cases evaluated). These mutations target critical functional domains (PR motif, proline rich domain, acidic region, and DNA-binding Zn-finger domain) involved in the regulation of different targets such as MYC. Furthermore, these mutations are found frequently in association with MYC translocations (5 out of 9, 56% of cases with MYC translocations were PRDM1-mutated), but not restricted to those cases, and lead to expression of an impaired PRDM1/Blimp1α protein.
    [Show full text]